Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
- Conditions
- Resectable Hepatocellular Carcinoma
- First Posted Date
- 2021-01-08
- Last Posted Date
- 2024-12-03
- Target Recruit Count
- 31
- Registration Number
- NCT04701060
- Locations
- 🇨🇳
Tianjin Medical University Cancer Insititute and Hospital, Tianjin, Tianjin, China
A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma
- Conditions
- Non-Hodgkin's B-cell Lymphoma
- Interventions
- Biological: Prizloncabtagene autoleucel
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2023-05-31
- Target Recruit Count
- 7
- Registration Number
- NCT04696432
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hosipital, Tianjin, Tianjin, China
Almonertinib With Chemotherapy in mEGFR NSCLC
- Conditions
- Non-Small Cell Lung Cancer Metastatic
- Interventions
- First Posted Date
- 2020-11-30
- Last Posted Date
- 2020-12-02
- Target Recruit Count
- 10
- Registration Number
- NCT04646824
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2020-11-17
- Target Recruit Count
- 33
- Registration Number
- NCT04631757
Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC
- Conditions
- Lung NeoplasmsLymph Node Excision
- Interventions
- Procedure: Systemic mediastinal lymph node dissectionProcedure: Spared mediastinal lymph node dissection
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2023-09-28
- Target Recruit Count
- 1362
- Registration Number
- NCT04631770
- Locations
- 🇨🇳
Ethics review board of Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy
- Conditions
- Triple-negative Breast Cancer
- Interventions
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2020-12-07
- Target Recruit Count
- 20
- Registration Number
- NCT04582955
- Locations
- 🇨🇳
Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China
Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial
- First Posted Date
- 2020-09-18
- Last Posted Date
- 2020-10-14
- Target Recruit Count
- 53
- Registration Number
- NCT04553887
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC
- Conditions
- Early Stage Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2020-11-13
- Target Recruit Count
- 30
- Registration Number
- NCT04530227
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China
- Conditions
- PalbociclibFulvestrantBreast Cancer
- Interventions
- First Posted Date
- 2020-08-25
- Last Posted Date
- 2020-08-25
- Target Recruit Count
- 612
- Registration Number
- NCT04526028
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)
- Conditions
- Stage IIIEsophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2023-04-10
- Target Recruit Count
- 50
- Registration Number
- NCT04389177
- Locations
- 🇨🇳
Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China